Table 2 Relative investment in type of science for HIV, tuberculosis and malaria research, as described by a ‘UK pound per publication’ metric
Preclinical | Phase I–III | Product development | Public health | Total | |
|---|---|---|---|---|---|
HIV | |||||
Funding 1997–2010 | £220,563,052 | £111,316,004 | £23,783,625 | £160,119,168 | £515,781,849 |
Publications 1997–2013 | 1,832 | 341 | 284 | 5,866 | 8,323 |
Pound per publication | £120,395 | £326,440 | £83,745 | £27,296 | £61,971 |
Tuberculosis | |||||
Funding 1997–2010 | £96,477,706 | £11,605,445 | £20,172,857 | £39,735,452 | £167,991,460 |
Publications 1997–2013 | 1,275 | 62 | 193 | 1,784 | 3,314 |
Pound per publication | £75,669 | £187,185 | £104,523 | £22,273 | £50,691 |
Malaria | |||||
Funding 1997–2010 | £202,459,316 | £9,920,472 | £12,839,850 | £156,302,225 | £381,521,863 |
Publications 1997–2013 | 2,112 | 164 | 138 | 1,624 | 4,038 |
Pound per publication | £95,861 | £60,491 | £93,042 | £96,245 | £94,483 |